Society for Clinical Research Sites Announces TransCelerate BioPharma’s Ongoing Commitment to Partnership with SCRS Site Advocacy Groups
Contact:
Diana Foster, Ph.D.
Vice President, Strategy & Development
Society for Clinical Research Sites
(214) 263-1094
diana.foster@myscrs.org
FOR IMMEDIATE RELEASE
Society for Clinical Research Sites Announces TransCelerate BioPharma’s Ongoing Commitment to Partnership with SCRS Site Advocacy Groups
Ellicott City, MD, April 19, 2016 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, continues to ensure the site’s voice is heard and positively influencing decisions of industry stakeholders. Since its inception in early 2014 the Site Advocacy Group (SAG) initiative has expanded robustly among forward thinking organizations. Ensuring the sites’ voices is considered within the SAG projects and protocols they are engaged in has been transformational for all stakeholders. This pioneering initiative has provided important dialogue on over 20 initiatives between site professionals, eight industry partners and TransCelerate BioPharma, Inc.
“Through our partnership with SCRS, key TransCelerate Initiatives have gained significant insight and feedback directly from investigative sites. TransCelerate aims to deliver impact to benefit the broader clinical ecosystem and everything that we’ve done so far will have an impact on sites. The value of the interactions through the SCRS Site Advocacy Groups is immeasurable. Together, we are addressing some of our industry’s greatest challenges,” stated Janice Chang, Senior Vice President, Global Operations, TransCelerate BioPharma, Inc.
“On behalf of all sites, SCRS is deeply appreciative and applauds TransCelerate and other organizations committed to site engagement through the SAG program. While sites may not be the ultimate decision maker of the end products such as protocols, technology, or new processes, they are often the end user. Including the site perspective is the most strategic business tactic an organization could undertake” states Christine Pierre, SCRS President. “Through our ongoing partnership with TransCelerate and other stakeholders, SCRS will continue to ensure the site’s perspective illuminates the difficult challenges sites face and together reach collective goals.”
The opportunity to participate in a SAG is available to all SCRS members and any organization desiring to include the site’s voice in their decision making process. Two new SAGs (eConsent and eLabels) are about to be launched to support two of TransCelerate’s newest initiatives.
###
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 2,600 research sites in 42 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
About TransCelerate BioPharma, Inc.
TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by accelerating and enhancing the research and development (R&D) of innovative new therapies. The organization’s mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry, and examine solutions for addressing common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Amgen, Astellas Pharma Inc., EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Medgenics, Inc., Merck & Co., Inc., Novo Nordisk, Shionogi & Co., Ltd. and UCB.
Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. Executive offices are located in Philadelphia, PA. For more information, please visit http://www.transceleratebiopharmainc.com.
